CDKN2B and chronic myelogenous leukemia, BCR-ABL1 positive: Jelinek et al., 2011 studied the Methylation levels of 10 genes in CML patients and found that the frequency of methylated genes ranged from 11%to 86% as follows: ABL1 (86%), CDH13 (79%), NPM2 (74%), PGRA (66%), TFAP2E (63%), DPYS (54%), PGRB (52%),OSCP1 (30%), PDLIM4 (21%), and CDKN2B (11%), suggesting an aberrant methylation of DNA associated with the progression of the disease (Jelinek et al., 2011).